AutoGenomics IPO Will Support Trial Of HPV Test On Infiniti Analyzer
This article was originally published in The Gray Sheet
AutoGenomics is seeking to fund a clinical study of its HPV-QUAD human papillomavirus screening test through an initial public stock offering worth up to $86.3 million (see chart: "1AutoGenomics IPO")
You may also be interested in...
Financings In Brief
Molecular diagnostics firm AutoGenomics seeks to raise up to $65 million in an initial public offering. IlluminOss raises $28 mil. for fracture repair device. LoneStar Heart gets $20 million for heart failure implant. More financings.
Hologic Gains HPV Test Technology In $580 Million Third Wave Purchase
Hologic's purchase of molecular diagnostics firm Third Wave Technologies for $580 million provides a platform for near-term entry into the expanding, $200 million U.S. market for human papillomavirus testing
FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development
US FDA Commissioner Califf praises both Project Pragmatica and the ‘very powerful’ partnership between OCE Director Rick Pazdur and National Cancer Institute Director Monica Bertagnolli.